Xolair Archives -

Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic spontaneous urticaria

Dupixent falls short in phase 3 chronic spontaneous urticaria trial

https://pharmaphorum.com/news/dupixent-falls-short-in-phase-3-chronic-spontaneous-urticaria-trial/

Novartis’ big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many

Blow for Novartis as ligelizumab can’t top Xolair in phase 3

https://pharmaphorum.com/news/blow-for-novartis-as-ligelizumab-cant-top-xolair-in-phase-3/

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many

Ligelizumab could top Xolair in chronic hives, says Novartis

https://pharmaphorum.com/news/ligelizumab-could-top-xolair-in-chronic-hives-says-novartis/

Novartis says it intends to move a drug for chronic spontaneous urticaria (CSU), a severe form of hives,

Novartis takes Xolair follow-up into phase III hives trial

https://pharmaphorum.com/news/novartis-takes-xolair-follow-up-into-phase-iii-hives-trial/

Xolair, a drug developed 15 years ago by Roche and Novartis, received a breakthrough designation from the US

Breakthrough designation for Roche/Novartis’ Xolair in food allergies

https://pharmaphorum.com/news/breakthrough-designation-for-roche-novartis-xolair-in-food-allergies/

Xolair has gained EU approval as the first ever add-on therapy to treat chronic spontaneous urticaria (CSU) in

New dermatology licence for Xolair

https://pharmaphorum.com/news/new-dermatology-licence-for-xolair/

Xolair